NASDAQ:LGND

Ligand Pharmaceuticals - LGND Stock Forecast, Price & News

$69.72

-6.89 (-8.99%)

(As of 01/26/2023 05:35 PM ET)

Add

Compare

Today's Range: $69.00
▼
$78.00
50-Day Range: $62.15
▼
$78.50
52-Week Range: $57.77
▼
$128.51

Volume: 186,094 shs
Average Volume: 113,206 shs
Market Capitalization: $1.18 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $119.00

Institutional Ownership

Ligand Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 70.7% Upside
$119.00 Price Target
Short Interest: Bearish
5.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.57
Upright™ Environmental Score
News Sentiment: 1.39
Based on 4 Articles This Week
Insider Trading: Selling Shares
$1.53 M Sold Last Quarter
Proj. Earnings Growth: -44.68%
From $2.35 to $1.30 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

144th out of 1,048 stocks

Pharmaceutical Preparations Industry

62nd out of 513 stocks

3.5

Analyst's Opinion

Consensus Rating
Ligand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $119.00, Ligand Pharmaceuticals has a forecasted upside of 70.7% from its current price of $69.72.
Amount of Analyst Coverage
Ligand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.06% of the float of Ligand Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Ligand Pharmaceuticals has recently increased by 1.54%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Ligand Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ligand Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ligand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Ligand Pharmaceuticals is -1.57.

3.0

News and Social Media Coverage

News Sentiment
Ligand Pharmaceuticals has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Ligand Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,530,185.00 in company stock.
Percentage Held by Insiders
10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
87.16% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Ligand Pharmaceuticals are expected to decrease by -44.68% in the coming year, from $2.35 to $1.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ligand Pharmaceuticals is -56.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ligand Pharmaceuticals is -56.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Ligand Pharmaceuticals has a PEG Ratio of 2.24. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Ligand Pharmaceuticals has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ligand Pharmaceuticals (NASDAQ:LGND) Stock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is based in San Diego, California.

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

January 23, 2023 | finance.yahoo.com

Shareholders in Ligand Pharmaceuticals (NASDAQ:LGND) are in the red if they invested five years ago

January 17, 2023 | americanbankingnews.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Recommendation of "Moderate Buy" from Analysts

January 26, 2023 | PressReach (Ad)

Stocks News Announcement

Don't miss this update. Read the press release about Small Pharma.

January 11, 2023 | finance.yahoo.com

Are Options Traders Betting on a Big Move in Ligand (LGND) Stock?

January 6, 2023 | finance.yahoo.com

Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

December 23, 2022 | msn.com

Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know

December 19, 2022 | finance.yahoo.com

Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?

December 13, 2022 | markets.businessinsider.com

Ligand Pharma Guides FY23 EPS Above View, But Revenue Shy Of Estimates

January 26, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

December 13, 2022 | finance.yahoo.com

Ligand Provides Highlights from its Investor and Analyst Day Event

December 13, 2022 | finance.yahoo.com

Is BioNTech (BNTX) Stock Undervalued Right Now?

December 13, 2022 | finance.yahoo.com

LGND or GMAB: Which Is the Better Value Stock Right Now?

December 13, 2022 | finance.yahoo.com

Ligand Pharma Issues Mixed Guidance For FY23

December 8, 2022 | finance.yahoo.com

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice

December 5, 2022 | marketwatch.com

Ligand Pharmaceuticals CEO Higgins Retires

December 5, 2022 | nasdaq.com

Is Now The Time OmniAb? 5 Insider Purchase And Two Bullish Initiations Propel Shares Almost 100% Higher Over The Week

December 5, 2022 | seekingalpha.com

OmniAb: Scalable Biotech Spinoff Opportunity, High Risk/High Reward

November 17, 2022 | finance.yahoo.com

Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium

November 16, 2022 | finance.yahoo.com

Ligand to Hold Investor and Analyst Day on December 13

November 15, 2022 | finance.yahoo.com

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

November 8, 2022 | finance.yahoo.com

Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook

November 8, 2022 | markets.businessinsider.com

Ligand Pharmaceuticals Inc Q3 Profit Decreases, but beats estimates

November 8, 2022 | finance.yahoo.com

Ligand Reports Third Quarter 2022 Financial Results

November 8, 2022 | finance.yahoo.com

Ligand Pharmaceuticals (LGND) Misses Q3 Earnings Estimates

November 4, 2022 | msn.com

Earnings Outlook For Ligand Pharmaceuticals

November 2, 2022 | finance.yahoo.com

Is There An Opportunity With Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) 50% Undervaluation?

November 1, 2022 | finance.yahoo.com

Ligand Announces Completion of OmniAb Spin-Off

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Company Calendar

Last Earnings: 11/07/2022
Today: 1/26/2023
Next Earnings (Estimated): 2/16/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:LGND
CUSIP: 53220K50
CIK: 886163
Web: www.ligand.com
Phone: (858) 550-7500
Fax: 858-550-1826
Employees: 154
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $119.00
High Stock Price Forecast: $160.00
Low Stock Price Forecast: $90.00
Forecasted Upside/Downside: +70.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 29.67
P/E Growth: 2.24
Net Income: $57.14 million
Net Margins: -8.62%
Pretax Margin: -11.15%
Return on Equity: 2.57%
Return on Assets: 1.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.63
Quick Ratio: 1.46

Sales & Book Value

Annual Sales: $277.13 million
Price / Sales: 4.25
Cash Flow: $8.49 per share
Price / Cash Flow: 8.21
Book Value: $49.14 per share
Price / Book: 1.42

Miscellaneous

Outstanding Shares: 16,894,000
Free Float: 15,137,000
Market Cap: $1.18 billion
Optionable: Optionable
Beta: 1.10

Key Executives

Mr. Todd C. Davis (Age 62)
CEO & Director
Comp: $65.05k

Mr. Matthew E. Korenberg (Age 48)
Pres & COO
Comp: $753.25k

Mr. Octavio Espinoza
Chief Financial Officer

Simon Latimer
Head of Investor Relations

Mr. Andrew T. Reardon J.D.
Chief Legal Officer

Mr. Todd Pettingill
Director of Corp. Devel.

Ms. Audrey Warfield-Graham
Chief People Officer

Dr. Keith Marschke
Sr. VP of Biology & Scientific Affairs

Dr. Vincent D. Antle (Age 54)
Sr. VP of Technical Operations & QA - Capitsol

Mr. Patrick Lucy
Sr. VP & CBO Protein Expression Bus.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LGND Stock - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings or view top-rated stocks.
What is Ligand Pharmaceuticals' stock price forecast for 2023?: 4 brokers have issued 1 year price targets for Ligand Pharmaceuticals' shares. Their LGND share price forecasts range from $90.00 to $160.00. On average, they anticipate the company's stock price to reach $119.00 in the next twelve months. This suggests a possible upside of 55.3% from the stock's current price.
View analysts price targets for LGND or view top-rated stocks among Wall Street analysts.
How have LGND shares performed in 2023?: Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND stock has increased by 14.7% and is now trading at $76.61.
View the best growth stocks for 2023 here.
When is Ligand Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our LGND earnings forecast.
How were Ligand Pharmaceuticals' earnings last quarter?: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings data on Monday, November, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.29. The biotechnology company earned $66.09 million during the quarter, compared to analyst estimates of $38.47 million. Ligand Pharmaceuticals had a negative net margin of 8.62% and a positive trailing twelve-month return on equity of 2.57%.
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?: Ligand Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, December, 21st. The company provided earnings per share guidance of $4.30-$4.45 for the period, compared to the consensus earnings per share estimate of $4.24. The company issued revenue guidance of $184.00 million-$189.00 million, compared to the consensus revenue estimate of $212.82 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?: 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Ligand Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).
What is Ligand Pharmaceuticals' stock symbol?: Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
Who are Ligand Pharmaceuticals' major shareholders?: Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Villere ST Denis J & Co. LLC (2.86%), Chicago Capital LLC (1.89%), Woodstock Corp (0.33%), Allspring Global Investments Holdings LLC (0.17%), AMI Asset Management Corp (0.12%) and Yousif Capital Management LLC (0.06%). Insiders that own company stock include Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza and Todd C Davis.
View institutional ownership trends.
How do I buy shares of Ligand Pharmaceuticals?: Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ligand Pharmaceuticals' stock price today?: One share of LGND stock can currently be purchased for approximately $76.61.
How much money does Ligand Pharmaceuticals make?: Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.29 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or ($1.24) on an earnings per share basis.
How many employees does Ligand Pharmaceuticals have?: The company employs 154 workers across the globe.
How can I contact Ligand Pharmaceuticals?: Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.

This page (NASDAQ:LGND) was last updated on 1/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ligand Pharmaceuticals - LGND Stock Forecast, Price & News

Ligand Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ligand Pharmaceuticals (NASDAQ:LGND) Stock

LGND Stock News Headlines

LGND Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LGND Stock - Frequently Asked Questions

Overall MarketRank^™